Literature DB >> 27799390

Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases.

Alberto Ruano-Ravina1,2,3, María Torres-Durán4, Karl T Kelsey3, Isaura Parente-Lamelas5, Virginia Leiro-Fernández4, Ihab Abdulkader6, José Abal-Arca5, Carmen Montero-Martínez7, Iria Vidal-García7, Margarita Amenedo8, Olalla Castro-Añón9, Antonio Golpe-Gómez10, Javier González-Barcala10, Cristina Martínez11, Rosirys Guzmán-Taveras11, Mariano Provencio12, María José Mejuto-Martí13, Alberto Fernández-Villar4, Juan Miguel Barros-Dios14,2,15.   

Abstract

The aim of this study was to assess if residential radon exposure might cause EGFR mutations or ALK rearrangements in never-smokers.We designed a multicentre case-control study in a radon-prone area (Galicia, Spain); only lung cancer cases were included in the study. We obtained residential radon measurements and clinical information for all the participants. We compared the median values of residential radon between patients with EGFR mutations or ALK rearrangements versus those without them.323 patients were included. Median age was 70 years and 19.5% were males. 42 and 15% of patients were EGFR- and ALK-positive, respectively. The most frequent EGFR alterations were exon 19 deletions and exon 21 (L858R) single-point substitution mutations. ALK-positive patients were 10 years younger than ALK-negative patients. Residential radon levels were two-fold higher in patients with exon 19 deletions compared with patients with exon 21 (L858R) single-point substitution mutations (216 versus 118 Bq·m-3; p=0.057). There were no differences in residential radon levels by EGFR mutation status. ALK-positive patients (n=12) essentially had two-fold residential radon levels compared with ALK-negative patients (290 versus 164 Bq·m-3, respectively).Residential radon may have a role in the molecular signature of lung cancer in never-smokers, although more studies with larger sample sizes are needed to support this hypothesis.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27799390     DOI: 10.1183/13993003.00407-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

Review 1.  Lung cancer as a cardiotoxic state: a review.

Authors:  David Pérez-Callejo; María Torrente; María Auxiliadora Brenes; Beatriz Núñez; Mariano Provencio
Journal:  Med Oncol       Date:  2017-08-09       Impact factor: 3.064

2.  Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.

Authors:  Sabine Schmid; Mei Jiang; Wei Xu; Geoffrey Liu; M Catherine Brown; Aline Fares; Miguel Garcia; Joelle Soriano; Mei Dong; Sera Thomas; Takashi Kohno; Leticia Ferro Leal; Nancy Diao; Juntao Xie; Zhichao Wang; David Zaridze; Ivana Holcatova; Jolanta Lissowska; Beata Świątkowska; Dana Mates; Milan Savic; Angela S Wenzlaff; Curtis C Harris; Neil E Caporaso; Hongxia Ma; Guillermo Fernandez-Tardon; Matthew J Barnett; Gary Goodman; Michael P A Davies; Mónica Pérez-Ríos; Fiona Taylor; Eric J Duell; Ben Schoettker; Hermann Brenner; Angeline Andrew; Angela Cox; Alberto Ruano-Ravina; John K Field; Loic Le Marchand; Ying Wang; Chu Chen; Adonina Tardon; Sanjay Shete; Matthew B Schabath; Hongbing Shen; Maria Teresa Landi; Brid M Ryan; Ann G Schwartz; Lihong Qi; Lori C Sakoda; Paul Brennan; Ping Yang; Jie Zhang; David C Christiani; Rui Manuel Reis; Kouya Shiraishi; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-03-01       Impact factor: 4.090

3.  Elemental and mutational analysis of lung tissue in lung adenocarcinoma patients.

Authors:  Ryosuke Chiba; Naoto Morikawa; Koichiro Sera; Kazuyuki Ishida; Hiromi Nagashima; Wataru Shigeeda; Hiroyuki Deguchi; Makoto Tomoyasu; Takako Hosokawa; Hajime Saito; Tamotsu Sugai; Kohei Yamauchi; Makoto Maemondo
Journal:  Transl Lung Cancer Res       Date:  2019-11

4.  Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking.

Authors:  Lili Zhang; Lin Han; Xinmiao Wang; Yu Wei; Jinghui Zheng; Linhua Zhao; Xiaolin Tong
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

Review 5.  Radon Biomonitoring and microRNA in Lung Cancer.

Authors:  Rakhmet Bersimbaev; Alessandra Pulliero; Olga Bulgakova; Kussainova Asia; Akmara Aripova; Alberto Izzotti
Journal:  Int J Mol Sci       Date:  2020-03-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.